International audienceBackground: Guidelines suggest that patients discontinue Clopidogrel at least 5 days prior to coronary artery bypass grafting (CABG). Those with acute coronary syndrome (ACS) are at high risk for myocardial infarction (MI) if not treated with dual antiplatelet therapy (DAPT). We sought to assess pre and post-operative outcomes of patients maintained on Clopidogrel and aspirin up to the time of surgery and compare them with those on aspirin alone.Methods: From the cardiac surgery database, 240 patients were retrospectively registered between January and May 2017. There were 126 patients with ACS who underwent CABG on DAPT (Clopidogrel group [CG]) and 114 patients who underwent elective CABG on aspirin alone (control). T...
The optimal timing of discontinuation of ticagrelor before cardiac surgery is controversial.Importan...
ObjectivePatients presenting with acute coronary syndrome (ACS) are treated with dual antiplatelet a...
AbstractObjectivesThis study was designed to evaluate the effect of preoperative clopidogrel on coro...
Abstract Background We assessed the effectiveness of ...
Background The optimal antiplatelet therapy after coronary artery bypass grafting remains unclear. W...
We sought to evaluate the outcomes of postoperative three-month dual antiplatelet therapy in patient...
Abstract Background: Coronary artery disease remains the dominant cause of mortality in developed co...
Background: Early vein graft occlusion after coronary artery bypass grafting (CABG) is one of the ma...
Aim: To evaluate retrospectively the impact of ticagrelor or clopidogrel in patients taking dual ant...
OBJECTIVES: To evaluate the relationship between the timing of either ticagrelor or clopidogrel disc...
Importance: The optimal timing of discontinuation of ticagrelor before cardiac surgery is controvers...
Coronary artery bypass grafting is pivotal in the contemporary management of complex coronary artery...
Introduction: Dual antiplatelet therapy reduces the risk of cardiovascular death, myocardial infarct...
Objectives: There is still little evidence to support routine dual antiplatelet therapy (DAPT) with ...
Objective: Patients presenting with acute coronary syndrome (ACS) are treated with dual antiplatelet...
The optimal timing of discontinuation of ticagrelor before cardiac surgery is controversial.Importan...
ObjectivePatients presenting with acute coronary syndrome (ACS) are treated with dual antiplatelet a...
AbstractObjectivesThis study was designed to evaluate the effect of preoperative clopidogrel on coro...
Abstract Background We assessed the effectiveness of ...
Background The optimal antiplatelet therapy after coronary artery bypass grafting remains unclear. W...
We sought to evaluate the outcomes of postoperative three-month dual antiplatelet therapy in patient...
Abstract Background: Coronary artery disease remains the dominant cause of mortality in developed co...
Background: Early vein graft occlusion after coronary artery bypass grafting (CABG) is one of the ma...
Aim: To evaluate retrospectively the impact of ticagrelor or clopidogrel in patients taking dual ant...
OBJECTIVES: To evaluate the relationship between the timing of either ticagrelor or clopidogrel disc...
Importance: The optimal timing of discontinuation of ticagrelor before cardiac surgery is controvers...
Coronary artery bypass grafting is pivotal in the contemporary management of complex coronary artery...
Introduction: Dual antiplatelet therapy reduces the risk of cardiovascular death, myocardial infarct...
Objectives: There is still little evidence to support routine dual antiplatelet therapy (DAPT) with ...
Objective: Patients presenting with acute coronary syndrome (ACS) are treated with dual antiplatelet...
The optimal timing of discontinuation of ticagrelor before cardiac surgery is controversial.Importan...
ObjectivePatients presenting with acute coronary syndrome (ACS) are treated with dual antiplatelet a...
AbstractObjectivesThis study was designed to evaluate the effect of preoperative clopidogrel on coro...